Corporation
Becton Dickinson Canada Inc
- Meetings this Parliament
- 11
- With MPs
- 4
- Since Nov 2021
- 16
- Active registrations
- 1
Most recent reported meeting: Apr 30, 2026.
Lobbying by Becton Dickinson Canada Inc: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Apr 29, 2026
Filed by Ivy Parks, President
Lobbyists
- Enoch Owusu · Director of Regulatory Affairs
- Ivy Parks · President
- Robyn Saccon · Vice President, Public Affairs
Institutions they may lobby: CUSMA Secretariat, Canadian Institutes of Health Research (CIHR), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Invest in Canada Hub, National Defence (DND), National Research Council (NRC), Prime Minister's Office (PMO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (10)Hide details
- Government Bill (Senate)- Bill S-5 - Connected Care-An Act respecting the interoperability of health information technology and to prohibit data blocking by health information technology vendors
- Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector
- Public Bill (Senate) S-243- National Framework for Women's Health
- Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, health system planning and resilience.
- Canadian-United States-Mexico Agreement (CUSMA) with respect to provisions relating to medical devices and technologies
- Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export.
- Federal budget with respect to medical technology and device innovation and adoption, support and delivery of new models of care, equitable healthcare access, innovation, women’s health, and investments in long-term care and home care
- Discuss policies around healthcare system resiliency, health system planning, infection prevention, medication errors, women's health, and health equity including access
- Regulations under the Food and Drugs Act, including the Medical Devices Regulation, with respect to the approval of medical technologies
- Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Registration 951016-360496-20. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Ivy Parks · In-house (corporation)
- Marjorie Michel · Minister of Health
Discuss policies around healthcare system resiliency, health system planning, infection prevention, medication errors, women's health, and health equity including access Read more
Government Bill (Senate)- Bill S-5 - Connected Care-An Act respecting the interoperability of health information technology and to prohibit data blocking by health information technology vendors
Public Bill (Senate) S-243- National Framework for Women's Health
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, health system planning and resilience.
-
Reported by Ivy Parks · In-house (corporation)
- Timothy Smith · Deputy Program Manager, National Defence (DND)
Discuss policies around healthcare system resiliency, health system planning, infection prevention, medication errors, women's health, and health equity including access Read more
-
Reported by Ivy Parks · In-house (corporation)
- Justine Frame · Policy Advisor, Health Canada (HC)
Discuss policies around healthcare system resiliency, health system planning, infection prevention, medication errors, women's health, and health equity Read more
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export.
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Federal budget with respect to medical technology and device innovation and adoption, support and delivery of new models of care, equitable healthcare access, innovation, women’s health, and investments in long-term care and home care
-
Reported by Ivy Parks · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export. Read more
Discuss policies around healthcare system resiliency, health system planning, infection prevention, medication errors, women's health, and health equity
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
-
Reported by Ivy Parks · In-house (corporation)
- Rechie Valdez · Member of Parliament
Discuss policies around healthcare system resiliency, health system planning, infection prevention, medication errors, women's health, and health equity Read more
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, health system planning and resilience.
-
Reported by Ivy Parks · In-house (corporation)
- Maninder Sidhu · Minister of International Trade, Global Affairs Canada (GAC)
- Iqra Khalid · Member of Parliament
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes. Read more
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector
Canadian-United States-Mexico Agreement (CUSMA) with respect to provisions relating to medical devices and technologies
-
Reported by Ivy Parks · In-house (corporation)
- Adam van Koeverden · Secretary of State- Sport
Discuss policies around healthcare system resiliency, infection prevention, medication errors, women's health, and health equity
-
Reported by Ivy Parks · In-house (corporation)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- bruce randall · Director General, Health Canada (HC)
- Connor MacDonald · Director General, Health Canada (HC)
- Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
and 1 moreShow fewer
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
Canadian-United States-Mexico Agreement (CUSMA) with respect to provisions relating to medical devices and technologies Read more
Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes.
Federal budget with respect to medical technology and device innovation and adoption, support and delivery of new models of care, equitable healthcare access, women’s health, and investments in long-term care and home care
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export.
Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, antimicrobial resistance, and diagnostic testing.
Discuss policies around healthcare system resiliency, infection prevention, medication errors, women's health, and health equity
Regulations under the Food and Drugs Act, including the Medical Devices Regulation, with respect to the approval of medical technologies
-
Reported by Ivy Parks · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector Read more
-
Reported by Ivy Parks · In-house (corporation)
- Jean Pierre Mizero · Manager of Stakeholder Relations, Innovation, Science and Economic Development Canada (ISED)
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export. Read more
-
Reported by Ivy Parks · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Federal life sciences strategy with respect to global value chain and supply chain management and investment towards medical technology manufacturing and export. Read more
-
Reported by Ivy Parks · In-house (corporation)
- Leah Taylor Roy · Member of Parliament, House of Commons
Economic DevelopmentHealthScience and Technology
-
Reported by Ivy Parks · In-house (corporation)
- Matthew Trnkus · Senior Advisor (Global Health), Global Affairs Canada (GAC)
- Qasir Hanif · Director of Stakeholder Relations, Global Affairs Canada (GAC)
- Aram Shoujounian · Policy Coordinator, Global Affairs Canada (GAC)
- Eshan Naik · Director of Policy, Health Canada (HC)
and 1 moreShow fewer
- Ophelia John · Senior Policy Advisor, Health Canada (HC)
Economic DevelopmentGovernment ProcurementHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Ivy Parks · In-house (corporation)
- Dan Albas · Member of Parliament
- Don Davies · Member of Parliament
- Shuvaloy Majumdar · Member of Parliament
- Stephen Ellis · Health Critic, Chair of HESA, House of Commons
and 4 moreShow fewer
- Robert Kitchen · Member of Parlilament, House of Commons
- Peter Scheifke · Member of Parliament, House of Commons
- Ophelia John · Senior Policy Advisor, House of Commons
- Chelsea Madryga · Policy and Parliamentary Secretary Advisor, Health Canada (HC)
Economic DevelopmentHealthResearch and DevelopmentScience and Technology
-
Reported by Ivy Parks · In-house (corporation)
- Stephen Bent · VP PHAC, Public Health Agency of Canada (PHAC)
- Joel Denis · Director General, Public Health Agency of Canada (PHAC)
Health
-
Reported by Ivy Parks · In-house (corporation)
- Rodrigo Arancibia · Director for Innovation, Science and Economic Development Canada, Innovation, Science and Economic Development Canada (ISED)
- Kate Cavallaro · Manager, Innovation, Science and Economic Development Canada (ISED)
- Sheryl Groeneweg · Director General, Innovation, Science and Economic Development Canada (ISED)
- roopa prihar · Policy Analyst, Innovation, Science and Economic Development Canada (ISED)
and 7 moreShow fewer
- Eric Bourbonnais · Associate Director, Innovation, Science and Economic Development Canada (ISED)
- Grace Chen · Advisor, Health Canada (HC)
- Andrea Adamson · Regional Regulatory Compliance and Enforcement Specialist, Health Canada (HC)
- Nadine Bourdeau · Regional Regulatory Compliance and Enforcement Specialist, Health Canada (HC)
- Aziz Haddad · Biomedical Engineer, Health Canada (HC)
- Michael Collins · Director General, Health Canada (HC)
- Kassondra Tyers · Analyst, Statistics Canada (StatCan)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.